Lymphomas News

Expert Shares Insight on Developments in T-Cell Lymphoma - OncLive



OncLive
 
Expert Shares Insight on Developments in T-Cell Lymphoma 
OncLive
Brammer: T-cell lymphomas have been an area of limited progress and poor overall prognosis. Over the past several years, we've had some exciting new developments. One of the most exciting developments is brentuximab vedotin, which is now being ...

 


Dover 7-year-old has had 500 straight days of chemo treatments, another year to go - The News Journal



The News Journal
 
Dover 7-year-old has had 500 straight days of chemo treatments, another year to go 
The News Journal
Yet Von ? whose alter ego is Voninja: The Lymphoma Ninja Warrior ? has taken it all in stride. When he was diagnosed with t-cell lymphoblastic lymphoma in May 2016, the kindergartner proudly told nurses that he was going to fight off the cancer. "I'm ...

 


Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of ... - GlobeNewswire (press release)



Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of ... 
GlobeNewswire (press release)
The Phase 1b multi-center, open-label study is designed to evaluate the safety and efficacy of ADU-S100 (MIW815) in combination with PDR001 in patients with accessible solid tumors or lymphomas. The trial will evaluate two treatment schedules of ...
Early-stage study of combination of Aduro's ADU-S100 and Novartis' PDR001 underway Seeking Alpha

all 2 news articles » 


Combination Therapy's Role in Follicular Lymphoma - OncLive



OncLive
 
Combination Therapy's Role in Follicular Lymphoma 
OncLive
Anas Younes, MD: There are 4 isoforms for PI3 kinase?alpha, beta, gamma, and delta?and there are drugs that you can selectively target 1 or more of these isoforms with. So, idelalisib targets delta, duvelisib targets gamma and delta, and copanlisib ...

 


Partnership to Develop Personalized Therapeutics for B-cell Lymphoma and Leukemia - Markets Insider



Markets Insider
 
Partnership to Develop Personalized Therapeutics for B-cell Lymphoma and Leukemia 
Markets Insider
"Our first tumor targets include B-cell lymphomas and leukemias ? these cancer types have long been known to harbour proteins that are unique to these tumors, and that are nearly ideal targets for immunotherapy. The historical challenge with drugging ...

and more » 


Trillium Therapeutics' TTI-621 Program Featured at the EORTC ... - Marketwired (press release)



Trillium Therapeutics' TTI-621 Program Featured at the EORTC ... 
Marketwired (press release)
TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company ...

and more » 


New study identifies genes that can help in lymphoma treatment - Duke Chronicle



Duke Chronicle
 
New study identifies genes that can help in lymphoma treatment 
Duke Chronicle
Lymphoma patients who don't respond to chemotherapy may be able to seek alternative treatment more quickly, thanks to new research from Duke. Duke Cancer Institute researchers analyzed tumor samples from 1,001 patients with diffuse large B cell ...

 


Copanlisib Tested in Relapsed/ Refractory Indolent Lymphoma - MedPage Today



Copanlisib Tested in Relapsed/ Refractory Indolent Lymphoma 
MedPage Today
The kinase inhibitor copanlisib (Aliqopa), recently approved as third-line therapy for relapsed follicular lymphoma, appeared safe and effective in patients with relapsed or refractory indolent lymphoma, according to a phase II study. Of the 142 ...

 


INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study - Markets Insider



INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study 
Markets Insider
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) announces that final results of the dose-escalation part of the ongoing Phase I study investigating IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas (CTCL), ...

and more » 


Thousands of blood cancer patients to receive cutting-edge tests, as ... - The Age



The Age
 
Thousands of blood cancer patients to receive cutting-edge tests, as ... 
The Age
Thousands of blood cancer patients will get access to potentially life-saving testing, with some able to avoid chemotherapy as a result, thanks to a new cancer ...

and more »